抗HBV-DC联合药物治疗e抗原阳性的临床研究
[摘要]目的 观察HBsAg致敏自体外周血单个核细胞（PBMC）来源的树突状细胞联合拉米夫定和胸腺肽α1治疗HBeAg阳性慢乙肝的临床效果。 方法 HBeAg阳性CHB患者20例接受临床研究。取肝素抗凝外周静脉血50mL，以密度梯度离心及贴壁法获得PBMC，GM-CSF和IL-4诱导扩增DC，第6天给予30 μg的HBsAg致敏DC，第7天收获抗HBV-DC。联合拉米夫定和胸腺肽α1，分别于0、4、12周检测HBVM定量和HBV-DNA定量及肝功能。 结果 全部患者治疗后4、12周的HBsAg、HBeAg和HBV-DNA均明显下降。总有效率100%（20/20）。 结论 抗HBV-DC联合拉米夫定和胸腺肽α1治疗，可快速降低血中HBsAg、HBeAg和HBV-DNA，促进HBeAb的产生，提高HBeAg/HBeAb的血清学转换率。
[关键词] 树突状细胞；慢性乙型肝炎；乙肝疫苗
[中图分类号] R512.62 [文献标识码] B [文章编号] 1673-9701（2012）01-077-03
Preliminary clinical study of anti-HBV-DC combine lamivudine and thymosin α1 treat the HBeAg positive chronic hepatitis B patients
LIU YongWU BangfuHU Yuanyuan
Gastroenterology and Hepatology Center, Southern Medical University Renkang Hospital, Dongguan523952, China
[Abstract] Objective To observe the clinical treatment effects of the HBsAg pulsed autologous dendritic cells derived from peripheral blood mononuclear cells (PBMC) combine lamivudine and Thymosin-α1 for the HBeAg positive chronic hepatitis B patients. Methods Twenty patients with HBeAg positive CHB accepted by clinical research. Taking peripheral venous blood 50mL, by density gradient centrifugation and adhesion method to obtain PBMC, GM-CSF and IL-4 induced expansion of DC. At the sixth days, a 30 μg HBsAg was give to pulse the DC. At the seventh days, the anti-HBV-DCs. All patients were Lamivudine dosed every day, and were injected thymosin-α1 by subcutaneous, The HBVM, HBV-DNA and liver function were respectively detected at 0,4,12 weeks. Results At 0,4,12 weeks, the serum HBsAg levels, the serum HBe...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
